A Study to Evaluate Family Member Exposure to Antineoplastic Drugs in the Home Setting

Overview

About this study

The purpose of this study is to quantify active antineoplastic drug metabolites in the urine samples, oral fluids, and skin of patients receiving intravenous chemotherapy on days 1 through 7 post infusion, to quantify active antineoplastic drug metabolites in the urine samples of family member/caregiver of patient receiving chemotherapy on days 1 through 7 post infusion, and to identify the instructions received by patient/family members to avoid exposure to contaminated bodily fluids from patients’ receiving intravenous antineoplastic drugs and whether the instructions were followed.

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Inclusion criteria for cancer patients are:

  • Age over 18 years.
  • Men or women.
  • On day 1 of any cycle of intravenous chemotherapy cycle containing at least one of the following drugs: 5-fluorouracil (5-FU), cyclophosphamide (CP) and platinum-compounds (cisplatin, carboplatin or oxaliplatin).
  • Any cancer staging.
  • Good performance status in order to avoid additional psychological stress (Eastern Cooperative Oncology Group performance status - ECOG >1, or Karnofsky Performance Status scale - KPS >80).

Inclusion criteria for family member or caregiver are:

  • Age over 18 years.
  • Men or women.
  • Live in the same house as the patient.
  • Not receiving any chemotherapy.

Exclusion Criteria: 

  • Patients/family members that are not able to communicate in English.
  • Irrespective of racial, religious, cultural backgrounds, will be excluded from the study.
  • If either the cancer patient or the family member does not consent to participate in the study, neither will participate; both should consent to be included in the study.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Eau Claire, Wis.

Mayo Clinic principal investigator

Jordan Dow, Pharm.D., R.Ph.

Open for enrollment

Contact information:

Dalete Mota Ph.D.

(715) 838-6937

Mota.Dalete@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20454963

Mayo Clinic Footer